Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Akebia Therapeutics
(NASDAQ:AKBA)
Intraday
$1.21
0
[0.00%]
After-Hours
$1.21
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.21
0
[0.00%]
At close: May 13
$1.21
0
[0.00%]
PreMarket: 4:05AM EDT
Get Report
Watch
Q1 2024 Earnings were released on Thu May 9th, before the market open
The most recent conference call was at 8:00 AM, 4 days ago
Click to view past webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Akebia Therapeutics Stock (NASDAQ:AKBA)
Akebia Therapeutics Stock (NASDAQ: AKBA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, May 09, 2024
Akebia Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.
Benzinga Newsdesk
-
3 days ago
Akebia Therapeutics Q1 2024 GAAP EPS $(0.09) Misses $(0.08) Estimate, Sales $32.607M Miss $46.087M Estimate
Benzinga Newsdesk
-
3 days ago
Wednesday, April 10, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Apr 10, 2024, 8:09AM
Friday, March 29, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Mar 29, 2024, 12:30PM
Thursday, March 28, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Mar 28, 2024, 1:35PM
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6
Benzinga Newsdesk
-
Mar 28, 2024, 12:20PM
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
Vandana Singh
-
Mar 28, 2024, 9:50AM
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Mar 28, 2024, 8:21AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Mar 28, 2024, 8:06AM
Akebia Therapeutics shares are trading higher after the FDA approved Vafseo tablets for treatment of anemia due to chronic kidney disease in adult patients on dialysis.
Benzinga Newsdesk
-
Mar 28, 2024, 7:24AM
Reported Earlier, Akebia's Wins FDA Approval Of Vafseo® Tablets For Dialysis-Related Anemia Treatment
Benzinga Newsdesk
-
Mar 28, 2024, 1:51AM
Wednesday, March 27, 2024
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Mar 27, 2024, 10:03AM
Tuesday, March 26, 2024
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Mar 26, 2024, 1:45PM
Friday, March 15, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Mar 15, 2024, 1:31PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Mar 15, 2024, 9:06AM
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target
Benzinga Newsdesk
-
Mar 15, 2024, 6:27AM
Thursday, March 14, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Mar 14, 2024, 5:33PM
Recap: Akebia Therapeutics Q4 Earnings
Benzinga Insights
-
Mar 14, 2024, 5:25PM
Akebia Therapeutics Q4 Sales $56.200M Beat $55.393M Estimate
Benzinga Newsdesk
-
Mar 14, 2024, 4:36PM
Earnings Scheduled For March 14, 2024
Benzinga Insights
-
Mar 14, 2024, 5:52AM
Wednesday, March 13, 2024
Earnings Preview For Akebia Therapeutics
Benzinga Insights
-
Mar 13, 2024, 10:05AM
Tuesday, January 30, 2024
Akebia Secures $55M Term Loan Financing
Benzinga Newsdesk
-
Jan 30, 2024, 8:08AM
Wednesday, November 29, 2023
BTIG Assumes Akebia Therapeutics at Buy, Announces Price Target of $4
Benzinga Newsdesk
-
Nov 29, 2023, 7:31AM
Friday, November 17, 2023
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $5
Benzinga Newsdesk
-
Nov 17, 2023, 7:10AM
Wednesday, November 08, 2023
Akebia Therapeutics Reaffirms FY23 Net Product Revenue Guidance Of $170M - $175M For Auryxia
Benzinga Newsdesk
-
Nov 8, 2023, 7:42AM
Akebia Therapeutics Q3 EPS $(0.08), Inline, Sales $42.05M Miss $48.18M Estimate
Benzinga Newsdesk
-
Nov 8, 2023, 7:33AM
Earnings Scheduled For November 8, 2023
Benzinga Insights
-
Nov 8, 2023, 4:21AM
Tuesday, November 07, 2023
Earnings Outlook For Akebia Therapeutics
Benzinga Insights
-
Nov 7, 2023, 9:01AM
Wednesday, October 25, 2023
Akebia Receives FDA Acceptance Of Resubmission To NDA Of Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease
Benzinga Newsdesk
-
Oct 25, 2023, 8:33AM
Thursday, September 28, 2023
Akebia Therapeutics Resubmits New Drug Application To FDA For Vadadustat
Benzinga Newsdesk
-
Sep 28, 2023, 8:01AM
Wednesday, September 27, 2023
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $3.75 Price Target
Benzinga Newsdesk
-
Sep 27, 2023, 6:42AM
Tuesday, September 26, 2023
Akebia Lowered Auryxia Product Revenue Guidance To $170M-$175M For FY23 From $175M-$180M Due To An Unfavorable Impact From Market Dynamics, Volume And Payor Mix
Benzinga Newsdesk
-
Sep 26, 2023, 8:17AM
Australia's Therapeutic Goods Administration Has Approved Akebia Therapeutics' Vafseo (Vadadustat) For Anemia Associated With Chronic Kidney Disease In Adults On Chronic Maintenance Dialysis
Benzinga Newsdesk
-
Sep 26, 2023, 8:15AM
Monday, August 28, 2023
Analyst Highly Confident In Akebia Therapeutics' Kidney Disease-Associated Anemia Drug, Stock Soars
Vandana Singh
-
Aug 28, 2023, 2:31PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Aug 28, 2023, 1:31PM
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Benzinga Insights
-
Aug 28, 2023, 11:00AM
HC Wainwright & Co. Upgrades Akebia Therapeutics to Buy, Raises Price Target to $3.75
Benzinga Newsdesk
-
Aug 28, 2023, 6:30AM
Friday, August 25, 2023
Akebia Has Affirmed Its 2023 Auryxia Net Product Revenue Guidance Of $175M-$180M
Benzinga Newsdesk
-
Aug 25, 2023, 8:13AM
Akebia Therapeutics Q2 EPS $(0.06) Misses $(0.02) Estimate, Sales $56.38M Miss $59.10M Estimate
Benzinga Newsdesk
-
Aug 25, 2023, 8:11AM
Earnings Scheduled For August 25, 2023
Benzinga Insights
-
Aug 25, 2023, 7:39AM
Intuit, Hibbett And 3 Stocks To Watch Heading Into Friday
Lisa Levin
-
Aug 25, 2023, 4:25AM
Fear & Greed Index Moves To 'Fear' Zone Ahead Of Powell's Speech
Lisa Levin
-
Aug 25, 2023, 2:54AM
Thursday, August 24, 2023
Earnings Outlook For Akebia Therapeutics
Benzinga Insights
-
Aug 24, 2023, 10:00AM
Akebia Therapeutics Expects To Resubmit Vadadustat NDA In Q3 2023
Benzinga Newsdesk
-
Aug 24, 2023, 8:05AM
Friday, August 11, 2023
Akebia Therapeutics shares are trading lower after the company announced the late filing of its Q2 earnings and Form 10Q but reaffirmed its FY23 net product revenue guidance.
Benzinga Newsdesk
-
Aug 11, 2023, 12:36PM
HC Wainwright & Co. Reiterates Neutral on Akebia Therapeutics, Maintains $2 Price Target
Benzinga Newsdesk
-
Aug 11, 2023, 6:50AM
Thursday, August 10, 2023
Akebia Expects To Resubmit NDA For Vadadustat As Treatment For Anemia Due To CKD In Adult Patients On Dialysis In Q3 2023
Benzinga Newsdesk
-
Aug 10, 2023, 5:50PM
Akebia Therapeutics Reports Late Filing Of Its Q2 Earnings And Form 10-Q; Reaffirms 2023 Net Product Revenue Guidance Of $175M-$180M
Benzinga Newsdesk
-
Aug 10, 2023, 5:49PM
Tuesday, July 25, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Jul 25, 2023, 1:31PM
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Jul 25, 2023, 1:11PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch